A citation-based method for searching scientific literature

A Al-Janabi, Z Z N Yiu. Psoriasis (Auckl) 2022
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
224
50




Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
W Rungapiromnan, K J Mason, M Lunt, K McElhone, A D Burden, M K Rutter, R B Warren, C E M Griffiths, D M Ashcroft. J Eur Acad Dermatol Venereol 2020
17
50

Psoriasis pathogenesis and the development of novel targeted immune therapies.
Jason E Hawkes, Tom C Chan, James G Krueger. J Allergy Clin Immunol 2017
409
50

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
563
50

Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice.
N H Shear, M Hartmann, M Toledo-Bahena, A Katsambas, L Connors, Q Chang, R Yao, K Nograles, Z Popmihajlov. Br J Dermatol 2014
27
50

Clinicians' perspectives of shared care of psoriatic arthritis and psoriasis between rheumatology and dermatology: an interview study.
Daniel Sumpton, Elyssa Hannan, Ayano Kelly, David Tunnicliffe, Andrew Ming, Geraldine Hassett, Jonathan C Craig, Allison Tong. Clin Rheumatol 2021
3
50

Current status of TNF blocking therapy in heart failure.
S Gupta, C D Tripathi. Indian J Med Sci 2005
7
50



Tumor necrosis factor inhibitors in psoriasis: an update.
Francisco A Kerdel, Bruce E Strober. Semin Cutan Med Surg 2014
8
50

Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
Yinzhu Jin, Hemin Lee, Moa P Lee, Joan E Landon, Joseph F Merola, Rishi J Desai, Seoyoung C Kim. Arthritis Care Res (Hoboken) 2022
7
50

Position statement for the management of comorbidities in psoriasis.
E Dauden, A J Blasco, C Bonanad, R Botella, J M Carrascosa, E González-Parra, E Jodar, B Joven, P Lázaro, A Olveira,[...]. J Eur Acad Dermatol Venereol 2018
42
50

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams,[...]. Lancet 2019
121
50

Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
P M Brunner, C Conrad, R Vender, S Grond, C Schuster, H Patel, W Xu, J M Carrascosa Carrillo. Br J Dermatol 2021
3
50

Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept.
J C van Denderen, G J Blom, I E van der Horst-Bruinsma, B A C Dijkmans, M T Nurmohamed. Clin Rheumatol 2012
9
50

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
992
50

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Robert E Kalb, David F Fiorentino, Mark G Lebwohl, John Toole, Yves Poulin, Arnon D Cohen, Kavitha Goyal, Steven Fakharzadeh, Stephen Calabro, Marc Chevrier,[...]. JAMA Dermatol 2015
222
50


Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C.
S A R Siegel, K L Winthrop, B D Ehst, A Ortega Loayza. Br J Dermatol 2019
7
50

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Kenneth B Gordon, Richard G Langley, Craig Leonardi, Darryl Toth, M Alan Menter, Sewon Kang, Michael Heffernan, Bruce Miller, Regina Hamlin, Liberata Lim,[...]. J Am Acad Dermatol 2006
386
50

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
Andreas Kerschbaumer, Alexandre Sepriano, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Iain B McInnes, Johannes W J Bijlsma, Gerd R Burmester, Maarten de Wit,[...]. Ann Rheum Dis 2020
85
50

Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents.
Akihiro Yamada, Jingzhou Wang, Yuga Komaki, Fukiko Komaki, Dejan Micic, Atsushi Sakuraba. Aliment Pharmacol Ther 2019
29
50

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events.
Smriti Subedi, Yu Gong, Youdong Chen, Yuling Shi. Drug Des Devel Ther 2019
25
50


Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
Bruce E Strober, Yves Poulin, Francisco A Kerdel, Richard G Langley, Yihua Gu, Shiraz R Gupta, Martin M Okun, Kim A Papp. J Am Acad Dermatol 2011
56
50

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
A Deodhar, P J Mease, I B McInnes, X Baraliakos, K Reich, A Blauvelt, C Leonardi, B Porter, A Das Gupta, A Widmer,[...]. Arthritis Res Ther 2019
148
50

Safety of biologic agents for psoriasis in patients with viral hepatitis.
Nawaf AlMutairi, Hesham Alaadin Abouzaid. J Dermatolog Treat 2018
10
50

The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
P Gisondi, P Facheris, P Dapavo, S Piaserico, A Conti, L Naldi, S Cazzaniga, P Malagoli, A Costanzo. Br J Dermatol 2020
83
50

Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
Laetitia Penso, Rosemary Dray-Spira, Alain Weill, Laura Pina Vegas, Mahmoud Zureik, Emilie Sbidian. JAMA Dermatol 2021
15
50

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
530
50

Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.
Simone Garcovich, Clara De Simone, Giovanni Genovese, Emilio Berti, Massimo Cugno, Angelo Valerio Marzano. Front Pharmacol 2019
31
50

Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study.
Hsien-Yi Chiu, Ying-Ming Chiu, Nien-Feng Chang Liao, Ching-Chi Chi, Tsen-Fang Tsai, Chang-Yu Hsieh, Tsu-Yi Hsieh, Kuo-Lung Lai, Tsu-Man Chiu, Nan-Lin Wu,[...]. J Am Acad Dermatol 2021
16
50



Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Alan Menter, Bruce E Strober, Daniel H Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W Armstrong, Cody Connor, Kelly M Cordoro, Dawn M R Davis,[...]. J Am Acad Dermatol 2019
303
50


Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Richard B Warren, Catherine H Smith, Zenas Z N Yiu, Darren M Ashcroft, Jonathan N W N Barker, A David Burden, Mark Lunt, Kathleen McElhone, Anthony D Ormerod, Caroline M Owen,[...]. J Invest Dermatol 2015
256
50

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
50


Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.
S Gerdes, A Pinter, C Papavassilis, M Reinhardt. J Eur Acad Dermatol Venereol 2020
26
50

New Treatment Addressing the Pathogenesis of Psoriasis.
Michio Tokuyama, Tomotaka Mabuchi. Int J Mol Sci 2020
39
50

Psoriasis Pathogenesis and Treatment.
Adriana Rendon, Knut Schäkel. Int J Mol Sci 2019
438
50

Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.
Xavier Mariette, Frauke Förger, Bincy Abraham, Ann D Flynn, Anna Moltó, René-Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil,[...]. Ann Rheum Dis 2018
182
50

Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
Hsien-Yi Chiu, Rosaline Chung-Yee Hui, Yu-Huei Huang, Ruey-Yun Huang, Kai-Lung Chen, Ya-Chu Tsai, Po-Ju Lai, Ting-Shun Wang, Tsen-Fang Tsai. Acta Derm Venereol 2018
35
50

Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.
Andrea Chiricozzi, Emma Guttman-Yassky, Mayte Suárez-Fariñas, Kristine E Nograles, Suyan Tian, Irma Cardinale, Sergio Chimenti, James G Krueger. J Invest Dermatol 2011
414
50

Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.
J Sanz-Bueno, F Vanaclocha, I García-Doval, R Torrado, G Carretero, E Daudén, D Patricia Ruiz-Genao, M M Alsina-Gibert, B Pérez-Zafrilla, G Pérez-Rial,[...]. Actas Dermosifiliogr 2015
33
50

Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.
Sze-Wen Ting, Yi-Cheng Chen, Yu-Huei Huang. Clin Drug Investig 2018
31
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.